News
-
-
PRESS RELEASE
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
APONTIS PHARMA AG waives minimum acceptance condition in Zentiva's public purchase offer. Around 60% shares tendered. Management recommends acceptance. Cash consideration offers premium -
-
PRESS RELEASE
EV Nickel Reports Precious Metals Assays Associated with Elevated Nickel Mineralization in Hole Ev24-Car08 on the CarLang C Zone
EV Nickel Inc. announces significant nickel mineralization with high PGM values in CarLang C area, indicating potential for magmatic sulphide source. Exploration and testing programs ongoing -
-
PRESS RELEASE
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024, with revenue guidance adjusted. Novartis collaboration boosts revenues. Full-year forecast slightly lowered -
-
PRESS RELEASE
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva's public tender offer. Offer price of EUR 10.00 per share represents a premium. Acceptance period ends on 21 November 2024 -
-
